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doi:10.1016/j.jtcvs.2004.01.0301688 The Journal of Thoracic and CardObjective: This study was undertaken to assess whether different filter types or
ultrafiltration methods influence inflammatory markers in pediatric cardiac sur-
gery.
Methods: Forty-one children younger than 5 years were prospectively random-
ized to groups A (polyamid filter with conventional ultrafiltration), B (polyamid
filter with modified ultrafiltration), C (polysulfon filter with conventional ultra-
filtration), and D (polysulfon filter with modified ultrafiltration). Interleukin 6,
interleukin 10, tumor necrosis factor, terminal complement complex, and lac-
toferrin were measured before the operation (T0), before rewarming (T1), after
ultrafiltration (T2), at 6 (T3) and 18 hours (T4) after the operation, and in the
ultrafiltrate.
Results: All markers changed with both ultrafiltration methods, both filter types, and
in all groups (except tumor necrosis factor) along the T0 to T4 observation time (P
 .0001). Their patterns of changes were different for terminal complement com-
plex, with less decrease after use of the polysulfon filter (P  .05), and among
groups A through D for interleukin 6 (P .01), with more decrease in group C than
group A (P  .02). Interleukin 10 decreased with the polyamid filter (P  .001) but
not with the polysulfon filter. In the ultrafiltrate, tumor necrosis factor was higher
with the polysulfon filter than the polyamid filter (6.8  5 pg/mL vs 4.0  3.7
pg/mL, P  .05). The ultrafiltrate/plasma ratio of interleukin 6 was higher with
conventional ultrafiltration than modified ultrafiltration (0.018  0.017 vs 0.004 
0.007, P  .005).
Conclusions: The polysulfon filter showed a filtration profile for inflammatory
mediators superior to that of the polyamid filter for interleukin 6, tumor necrosis
factor, and interleukin 10. Interleukin 6 was most efficiently removed by conven-
tional ultrafiltration with a polysulfon filter, and tumor necrosis factor was best
removed by modified ultrafiltration with a polysulfon filter, whereas other inflam-
matory mediators were not influenced by filter type or ultrafiltration method.
Therefore combined conventional and modified ultrafiltration with a polysulfon
filter may currently be the most effective strategy for removing inflammatory
mediators in pediatric heart surgery.
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DThe proinflammatory response to cardiac sur-gery, induced by the production of cytokinestriggered by cardiopulmonary bypass(CPB),1-3 contributes significantly to postop-erative morbidity and mortality4 and is ac-centuated in pediatric patients.5,6 With ultra-
filtration, most of the excess free water and a part of these
mediators may be eliminated, and the inflammatory response
to CPB thus may be attenuated.4,7 Conventional ultrafiltration
(CUF), applied during the rewarming phase on CPB, and
modified ultrafiltration (MUF), performed immediately after
cessation of CPB, are both broadly used in pediatric cardiac
surgery.8-11However, conflicting data exist concerning their
efficacy in removing cytokines,4-6,9,12-15 and controversy has
mainly focused on differences in ultrafiltration methods but not
in filter performance. Additionally, comparison of results from
ultrafiltration studies are difficult because of variations in ul-
trafiltration techniques, equipment, definitions of study end
points, and cytokine measurements. Since 1973 different types
of hemofilters, mainly polycarbon, have been used to eliminate
the excess water from the priming volume according to the
pressure gradient principle. These filters have permanently
been improved, replaced by polyarylethersulfon filters (PSF) in
1986 and later by the most recent filter generation, the poly-
amid filter (PAF). PSF does not have ideal filtration properties,
because high pressure gradients are needed and filtration rates
can be controlled only approximately. The improved biocom-
patibility of the PAF, along with its reduced surface, effective-
ness of filtration under physiologic pressure, and excellent
handling properties, makes its use for ultrafiltration attractive.
The efficacy of these filters in removing inflammatory media-
tors, simultaneously taking into consideration different ultra-
filtration methods, has not however been investigated in a
direct comparative fashion so far. To optimize efficacy of
ultrafiltration, methods and filter types need be harmonized,
combining a particular ultrafiltration method with a specific
filter type, to allow more efficient elimination of cytokines.
The aim of this study was to assess the effectiveness of PSF
and PAF filters concerning elimination of cytokines in relation
to the ultrafiltration method used. Secondarily, we wanted to
define an optimal combination of filter type and ultrafiltration
method in pediatric cardiac surgery.
Patients and Methods
Patients
Forty-one pediatric patients scheduled for elective cardiac surgery
with the use of CPB were included in the study. Children 5 years
or older, those undergoing surgical procedures without CPB or
with CPB duration of less than 45 minutes, and those undergoing
emergency procedures were excluded from the study. Patients
were prospectively randomly assigned to 4 groups for type of filter
(PAF vs PSF) and mode of ultrafiltration (CUF vs MUF): group A,
PAF with CUF; group B, PAF with MUF; group C, PSF with CUF,
and group D, PSF with MUF. The study protocol was approved by
The Journal of Thoracicthe local ethical committee. Informed consent was obtained from
the parents of each child. Patients characteristics and operative
data are depicted in Table 1. Surgery consisted of ventricular septal
defect closure (n  15); repair of tetralogy of Fallot or double-
outlet right ventricle (n  6); complete atrioventricular canal
repair (n 4); Rastelli operation (n 2); patch enlargement plasty
of the ascending aorta, aortic arch, or pulmonary truncus (n  5);
arterial switch operation (n  2); tetralogy of Fallot reoperations
(n  2); and miscellaneous other procedures (n  5). No signif-
icant differences were observed between the groups with respect to
patients’ diagnoses and demographic data.
Surgical Technique
In all cases the surgical approach was through a median sternot-
omy with CPB and systemic hypothermia. Two patients were
operated on with a period of deep hypothermic circulatory arrest.
Cold antegrade blood cardioplegia without topical cooling and
warm reperfusion cardioplegia (hot shot) were routinely used.
Non–heparin-coated CPB circuits of different sizes were used,
with a Polystan Safe Mini oxygenator (Polystan, Vaerlose, Den-
mark) for children smaller than 5 kg and a Dideco Midiflow
oxygenator (Dideco, Mirandola, Italy) for children larger than 5
kg. Aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) at a
dosage of 300,000 kIU/1000 mL circulating volume (priming plus
blood volume) was added to the blood prime in all patients.
Heparin was given to achieve an activated clotting time greater
than 600 seconds. After cessation of CPB, protamine sulfate (Prota-
min; Bayer AG) was administered to reestablish preoperative acti-
vated clotting time. Mediastinal shed blood was not retransfused.
Anesthesia
All patients were given midazolam (Dormicum; Roche Pharma
AG, Reinach, Switzerland) at 0.5 to 1 mg/kg rectally for premed-
ication. Anesthesia was induced with thiopental (Pentothal; Abbott
AG, Baar, Switzerland) with midazolam or ketamine (Ketalar;
Pfizer AG, Zurich, Switzerland) with midazolam and continued
with high-dose fentanyl (Fentanyl-Jansson; Janssen-Cilag AG,
Baar, Switzerland) and isoflurane (Forene; Abbott AG) or ket-
amine infusion of 2 mg/kg. Muscle relaxation was achieved with
pancuronium (Pavulon; Organon AG, Pfa¨ffikon, Switzerland). Pa-
tients were mechanically ventilated with mixed air and oxygen
(40%-50%) and extubated in the intensive care unit. Hemodynam-
ics were routinely assessed by transesophageal echocardiography
and surgical introduction of a pulmonary artery pressure catheter.
For postoperative pain relief, patients were given morphine (Mor-
phin-HCl; Sintetica SA, Mendrisio, Switzerland) supplemented
with acetaminophen (INN: paracetamol, Dafalgan; UPSAmedica
GmbH, Baar, Switzerland). Patients received antibiotic prophy-
laxis with intravenous cefuroxime at 50 mg/kg and continued at
100 mg/(kg · d) (Zinacef; GlaxoSmithKline AG, Mu¨nchenbuchsee,
Switzerland) for at least 24 hours until all drains were removed.
Blood Sample Protocol
Blood samples for analysis of cytokine concentrations were col-
lected from the radial artery after induction of anesthesia (T0),
before rewarming (T1), after ultrafiltration (T2), at 6 (T3) and 18
hours (T4) after the operation. Blood was collected into sterile
ethylenediaminetetraacetic acid and serum tubes and immediately
and Cardiovascular Surgery ● Volume 127, Number 6 1689
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Dcentrifuged at 2000g for 15 minutes at 6°C. Plasma, ultrafiltrate,
and urine samples were stored in multiple aliquots at 70°C until
analysis and were thawed only once. At each time point the
hematocrit was measured.
Ultrafiltration Technique
CUF was started with rewarming until cessation of CPB and was
stopped after complete extraction of the priming volume. During
MUF, the aortic cannula was used to drain the blood across the
filter and one atrial cannula was used to return the filtered blood
without an auxiliary blood pump. Thus MUF was passively driven
by the gradient between aorta and right atrium and assisted by
application of vacuum (approximately 20 cm H2O) at the ultrafil-
trate outlet port of the filter. CPB was bypassed by this ultrafiltra-
tion circuit, and therefore only the patient volume was filterable.
MUF was started after cessation of CPB, as soon as the child was
hemodynamically stable, and performed for a period of 20 min-
utes. During aortic crossclamping, hemofiltration was performed
to eliminate 50% of the priming volume, and during CUF or MUF,
the residual 50% was eliminated. The volume filtered was replaced
1:1 with packed red blood cells until a hematocrit of 30% was
reached; thereafter, it was replaced with fresh-frozen plasma. In
groups A and B, a PAF (Jostra BC20 Blood Concentrator filter;
Jostra Medizintechnik AG, Hirrlingen, Germany) with a surface of
0.2 m2, a priming volume of 13 mL, a maximal transmembranous
gradient of 600 mm Hg, a luminal diameter of 22 m, and a
membrane thickness of 50 m was used. In groups C and D, a PSF
(Jostra BC60 Blood Concentrator filter; Jostra Medizintechnik
AG) with a surface of 0.65 m2, a priming volume of 55 mL, a
maximal transmembranous gradient of 600 mm Hg, a luminal diam-
TABLE 1. Patients characteristics and operative data
Variable
A
(n  11)
Age (y) 1.4 1.4
Body surface area (m2) 0.406 0.13
Operation time (min) 188.2 55
CPB time (min) 96.8 30
Aortic crossclamp time (min) 50.7 22
Lowest body temperature (°C) 28.8 5.1
Cardioplegia volume (mL/kg) 31.6 20.4
Ultrafiltration time (min) 28.5 11
Ultrafiltration volume (mL/kg) 115 66
Ultrafiltration rate maximum (mL/min) 72 79
Ultrafiltration rate minimum (mL/min) 62 72
Filter pressure gradient (mm Hg) 70 41
Hematocrit increase during
ultrafiltration (%)
5.6 4.4
Total blood loss (mL/kg) 25 13
RBC transfusion intraoperative (mL/kg) 111 104
RBC transfusion postoperative (mL/kg) 16 14
RBC transfusion total (mL/kg) 127 105
FFP transfusion intraoperative (mL/kg) 13 24*
FFP transfusion postoperative (mL/kg) 3 5†
FFP transfusion total (mL/kg) 16 24*
All values are mean  SD. RBC, Red blood cell concentrate; FFP, fresh-f
*P .02 versus group D.
†P .05 versus groups B and C.eter of 215 m, and a membrane thickness of 50 m was used.
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Interleukin (IL) 6, IL-10, and tumor necrosis factor  (TNF) were
measured with specific enzyme immunoassays (Pierce Endogen,
Rockford, Ill). To estimate activation of the complement system,
we chose the terminal soluble C5b-9 complement complex (TCC)
to reflect effector consequence of all three activation pathways
(classical, alternative, and mannose-binding protein). TCC was
also measured by enzyme immunoassay (Quidel, Mountain View,
Calif), as was lactoferrin (Oxis International, Inc, Portland, Ore).
All enzyme immunoassays were performed according to the rec-
ommendations of the manufacturers. All cytokine concentrations
(except those of the ultrafiltrate) were corrected for the actual
hematocrit to correct for the high variability of hemodilution.
Values measured below the detection limit of a specific test were
set equal to the lower limit for statistical analysis.
Statistics
Data are expressed as mean  SD. Percentages are given where
appropriate. Statistical analysis was performed with Statview 5.0.1
for Windows (SAS Institute Inc, Cary, NC). For continuous vari-
ables comparing serial values, repeated-measures analysis of vari-
ance was used. For within-group and between-group analyses, a
Mann-Whitney U test and a Fisher exact test were used, respec-
tively. Bonferroni correction was applied where appropriate.
Results
Intraoperative data were not different among the groups
(Table 1). In fact, CUF did not prolong CPB and MUF did
not prolong operation time. Total MUF time was signifi-
B
(n  11)
C
(n  10)
D
(n  9)
2.5 1.9 1.3 1.3 1.6 1.6
0.5 0.18 0.39 0.15 0.42 0.15
173.6 45 185.6 85 198.9 43
97.2 41 106 43 95 26
54.8 31 56.1 23 42.3 21
31.5 2.2 28.4 4.7 30.3 4.4
32.6 26.5 51 37.3 183 165
22.8 10 25.5 10 27.7 33
82.3 45 111.7 62 96.7 55
94 88 45 60 102 77
82 72 42 58 93 76
76 47 77 32 61 38
7.6 4.6 3.9 4.8* 8.9 3.3
32 23 25 16 20 10
73 48 119 70 122 55
18 17 11 9 6 9
91 49 130 69 128 57
21 24 16 19 42 37
9 8 12 12 11 15
31 29 28 21 54 43
plasma.rozencantly longer than total CUF time (defined as the sum of
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Dhemofiltration time during aortic crossclamp and MUF or
CUF time, 45.25  15.1 minutes vs 36.6  11.5 minutes, P
 .05). However, net CUF time was similar to net MUF
time (defined as CUF or MUF time without hemofiltration
time, 27  10.5 minutes vs 23.5  9.5 minutes, P  .05)
without significant differences among the groups. Ultrafil-
tration volumes, maximal and minimal ultrafiltration rates,
and pressure gradients were not significantly different
among the groups. Hematocrit increased in all groups dur-
ing ultrafiltration, demonstrating the efficacy of the ultrafil-
tration to hemoconcentrate. The increase in hematocrit was
higher with MUF than CUF, reaching statistical significance
for group D vs group C (P  .01; Table 1).
Inflammatory Markers
All inflammatory markers except TNF showed a marked
increase during surgery (IL-6, IL-10, TCC) or in the first 6
hours thereafter (IL-6, lactoferrin), with return to baseline
levels within 18 hours except for lactoferrin.
Repeated-measures analysis of variance (Figure 1, A-E)
revealed no significant effect of the ultrafiltration method
(CUF vs MUF) on IL-6, IL-10, TNF, lactoferrin, and TCC.
Plasma concentrations of all inflammatory markers changed
significantly with both ultrafiltration methods along the T0
to T4 observation time (P  .0001), but the patterns of
changes of all markers were not different between the
ultrafiltration methods. Testing the effect of the filter type
(PAF vs PSF) showed no significant difference regarding
IL-6, IL-10, TNF, and lactoferrin. Plasma concentrations of
all inflammatory markers changed significantly with both
filter types along the T0 to T4 observation time (P .0001),
but the patterns of changes of all markers were not different
between the filter types. With the use of PSF, TCC showed
a significantly different changing pattern than with PAF (P 
.05), with less decrease after filtration (Figure 1, D, Table 2).
Testing the effect of the 4 combinations of filter type and
ultrafiltration method on IL-6, IL-10, TNF, lactoferrin, and
TCC revealed no significant differences among groups A
through D. All markers except TNF changed significantly
along the T0 to T4 observation time (P  .0001). Only the
patterns of changes of IL-6 (Figure 1, A) were significantly
different among groups A through D (P  . 01), especially
between A and C (P  .02).
In analyzing the filtration (T1-T2) and immediate post-
filtration (T2-T3) periods, significant differences were de-
tected. During filtration, IL-6 increased significantly in
groups A (P  .005) and B (P  .005; Figure 1, A), with
both filter types (PAF P  .0001, PSF P  .0002) and both
ultrafiltration methods (CUF P  .0001, MUF P  .0001;
Table 3). IL-10 increased significantly only with the use of
PAF (P  .0002; Figure 1, B) but with either ultrafiltration
method (CUF P  .001, MUF P  .005; Table 3); not,
however, in groups A through D. TNF, lactoferrin, and TCC
The Journal of Thoracicdid not change significantly among groups A through D, nor
did they change with filter types or ultrafiltration methods
(Tables 2 and 3). At T2, IL-6 was significantly lower in
group C than in group D (352.5  678.2 vs 1464.0  855.8
pg/mL, P  .01) and lower after CUF than after MUF (P 
.03). After filtration (T2-T3), IL-6 decreased significantly
after the use of either filter type (PAF P  .0002, PSF P 
.005) but only after MUF (P  .0002), not after CUF or
within groups A through D. IL-10 decreased significantly
only after the use of PAF (P  .001) and with either
ultrafiltration method (CUF P  .01, MUF P  .01). TNF
decreased significantly only after MUF (P .002; Figure 1,
C) and TCC only after the use of PAF (P  .0005; Figure
1, D) and CUF (P  .005). In contrast, lactoferrin increased
significantly in group A (P .005; Figure 1, E), after use of
either filter type (PAF P  .0005, PSF P  .005) and after
CUF (P  .0001).
Ultrafiltrate
IL-6, IL-10, lactoferrin, and TCC concentrations in the
ultrafiltrate were not different among the groups (Table 4).
Lactoferrin levels were all below detection limit in all
groups. TNF concentrations were significantly higher after
the use of PSF than PAF (6.81  5.03 pg/mL vs 4.02 
3.67 pg/mL, P  .05) and higher in group D than in group
A (7.06 4.39 pg/mL vs 2.82 2 pg/mL, P .082; Figure
2, A). Additionally, the total amount of TNF was signifi-
cantly higher in group D than in group A (4750  2593.5
pg/mL vs 2434.2  2305.1 pg/mL, P  .05, Table 4).
Figure 2, B, illustrates the efficacy of the different ultrafil-
tration strategies and filter types in removing IL-6, as dem-
onstrated by the ratio of the ultrafiltrate to plasma concen-
trations. IL-6 was significantly better eliminated in group C
than in groups B (0.02  0.017 vs 0.005  0.009, P  .02)
and D (0.02  0.017 vs 0.003  0.003, P  .01), and there
was more effective elimination of IL-6 by CUF than MUF
(0.018  0.017 vs 0.004  0.007, P  .005). Ultrafiltration
was more effective in removing TNF than the other medi-
ators, with much higher mean ultrafiltrate/plasma ratios
(1.01 0.94, 2.22 2.27, 2.72 2.75, and 2.01 2.34 for
groups A, B, C, and D, respectively) without differences
between the groups.
Clinical Outcome
Clinical outcomes were similar in all groups and not influ-
enced by type of filter or ultrafiltration strategy. Death (1
patient in group C), multiorgan failure (1 patient in group
C), arrhythmias (4 patients in group B, and 2 in groups C
and D), infections (1 patient in groups A and D, and 2 in
groups B and C), renal failure requiring temporary dialysis
(1 patient in group C), revisions for bleeding (2 patients in
group C), and duration of postoperative ventilatory support
(group A 43.2  2.1 hours, group B 55.6  57.5 hours,
and Cardiovascular Surgery ● Volume 127, Number 6 1691
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Dgroup C 61.9  46 hours, group D 80.5  110.2 hours)
were all not significantly different among the groups. How-
ever, low cardiac output was significantly more frequent
after the use of PSF than PAF filters (P .02). Blood losses
were similar in all groups (Table 1), irrespective of filter
type or ultrafiltration method used. Intraoperative red blood
cell transfusion volume (92  81 mL/kg vs 120  62
mL/kg, P  .05) and total fresh-frozen plasma transfusion
volume (23  27 mL/kg vs 40  35 mL/kg, P  .05) were
Figure 1. Repeated-measures analysis of variance, P
depicted. A, Plasma concentrations of IL-6, stratified
groups A and B; section mark indicates P < .01 for g
stratified by filter types PAF and PSF. Asterisk indicate
Plasma concentrations of TNF, stratified by ultrafiltrati
MUF. D, Plasma concentrations of TCC, stratified by filt
E, Plasma concentrations of lactoferrin (LF), stratified blower with the use of PAF than PSF, whereas the intraop-
1692 The Journal of Thoracic and Cardiovascular Surgery ● Junerative fresh-frozen plasma requirement was significantly
lower with CUF than MUF (15  21 mL/kg vs 31  32
mL/kg, P  .05). Neither type of filter nor ultrafiltration
method influenced intensive care unit or hospital stay. How-
ever, group D patients had significantly longer intensive
care unit stays than did group A patients (9  7.4 days vs
4.8 2.1 days, P .05) and longer hospital stays than both
group A patients (21.8  19.9 days vs 21.8  19.9 days, P
 .05) and group C patients (21.8  19.9 days vs 11.5 
es for group effect, time effect, and interaction are
oups A, B, C, and D. Asterisk indicates P < .005 for
C versus group D. B, Plasma concentrations of IL-10,
.0002; double asterisk indicates P < .001 for PAF. C,
ethods CUF and MUF. Asterisk indicates P < .002 for
es PAF and PSF. Asterisk indicates P < .0005 for PAF.
oups A, B, C, and D. Asterisk indicates P < .005 for A.valu
by gr
roup
s P 
on m
er typ3.9 days, P  .05).
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DDiscussion
Ultrafiltration techniques have been shown to improve postop-
erative hemodynamics9,16,17 and recovery of myocardial,18
cerebral,19 respiratory,6,11 and hemostatic functions3,9 after pe-
diatric cardiac surgery, mainly because of their ability to elim-
inate excess free plasma water.3,9,10 Controversy exists regard-
ing their potential to remove proinflammatory mediators
(cytokines and complement factors) that play a major role in
the inflammatory response to CPB1,2 and in postoperative
9
TABLE 3. Plasma concentrations of IL-6, IL-10, and TNF ac
CUF MUF
IL-6
T0 13.7 38.1 5 5
T1 10.3 21.3 6.4 7
T2 773.7 1370.7*† 1083.4 8
T3 125.7 111 91 6
T4 84 136.3 50.8 3
IL-10
T0 12.7 15.4 46.2 1
T1 48.1 95.4 68.4 9
T2 101.8 108 108.4 1
T3 40.3 43.3 51.6 6
T4 51.4 79.4 35.7 4
TNF
T0 3.6 3.2 5.8 1
T1 5 6.5 4.7 6
T2 4.1 3.3 4.4 4
T3 4.6 5.5 2.7 2
T4 2.5 1.5 2.2 1
All values are mean  SD.
*P .05 for between-group difference at the same time point for CUF ve
†P .0001 for within-group difference from previous time point.
‡P .0005 for within-group difference from previous time point.
§P .005 for within-group difference from previous time point.
P .001 for within-group difference from previous time point.
TABLE 2. Plasma concentrations of lactoferrin and TCC ac
CUF M
Lactoferrin
T0 495.1 669.3 421.8
T1 632.4 727.6 544.3
T2 578.2 792.9 626.7
T3 1531.3 2023.7* 1463.7
T4 1159.6 1023.4 1012.7
TCC
T0 415.2 346.8 417.7
T1 533.2 333.9 654.4
T2 644.3 360 650.3
T3 378.5 301.1‡ 502
T4 375.9 274.6 388.8
All values are mean  SD.
*P .0001 for within-group difference from previous time point.
†P .0005 for within-group difference from previous time point.
‡P .005 for within-group difference from previous time point.morbidity of neonates and infants. Inconsistent results among
The Journal of Thoracicstudies published in the literature4,5,15 are partially explained
by different ultrafiltration methods with various end points and
different filter types with specific functional and physical prop-
erties.12 We wanted to analyze the influence of different filter
types on the elimination of inflammatory cytokines and define
the optimal combination of an ultrafiltration method with a
specific filter type. Such a combination should ultimately allow
more efficient elimination of cytokines.
Overall, there was little difference between the two ul-
ing to ultrafiltration method or filter type
PAF PSF
13.3 36.2 4.4 5.2
10.4 20 6.1 9.4
981.6 1344.6† 846.6 931.7‡
120.9 115.1‡ 96.4 56.6§
76.6 133.4 58.5 47
33.3 93.2 24.6 41.9
59.6 92.7 56.1 99.2
107.2 95.9‡ 102.1 114.5
40.8 59.3 51.1 52.4
35.9 44.4 51.2 78.8
3.5 3 6.3 13.8
4.8 6.3 4.9 7
3.7 3 4.9 5
4.2 5.2 3.1 3.3
2.5 1.6 2.2 .9
UF.
ing to ultrafiltration method or filter type
PAF PSF
.3 529.8 662.4 370.3 192.9
.1 714.8 706.9 444.3 192.2
718.3 957.1 458.2 209.9
4.1 1743.9 2014.3† 1215.6 1010‡
1.2 1169.7 995.5 1001.5 1147.3
.7 344.7 261.4 505.1 363.9
.6 616.2 364.7 564.7 358.8
.9 673.1 308.3 615.4 413.7
.8 398.7 283.3† 479.7 303.2
.4 302.9 254.9 465.7 266.3cord
.4
.1
93.4†
2.4‡
1.2
02.1
5
00.7§
7.5
3.4
3
.8
.7
.7§
rsus Mcord
UF
288
255
669
106
112
294
380
360
274
272trafiltration methods concerning their efficacy to remove
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Dinflammatory mediators from the blood. We found that the
ultrafiltration method itself was responsible for a measur-
able difference for IL-6, TNF, TCC, and lactoferrin. IL-6
plasma levels were significantly lower at the end of CUF
than both after MUF and after CUF with PSF. Accordingly,
the ultrafiltrate/plasma ratio of IL-6 was significantly higher
in the CUF group C than in the MUF groups B and D and
was higher with CUF than with MUF, indicating better
elimination of IL-6 with CUF than with MUF. Thus, IL-6
was removed to a significantly higher degree from the blood
with CUF than with MUF, especially when combined with
a PSF filter type, although no relevant differences in total
amount of IL-6 filtered were found among the groups. These
findings are similar to those of Wang and coworkers,15 who
also found lower plasma IL-6 concentrations after CUF than
MUF with PSF but without a higher ultrafiltrate/plasma
ratio of IL-6. They also found TNF to be more efficiently
eliminated with MUF. Theoretically it would be more ap-
pealing to eliminate the inflammatory mediators by CUF
during rewarming, the moment of their maximal release.5,20
In accordance with Journois and coworkers, who found IL-6
and TNF significantly lowered with CUF and PSF in their
first study6 and IL-6, TNF, IL-10, and C3a better eliminated
with combined zero-balanced CUF and MUF than MUF
alone with a polynitril filter in their second study,4 our
findings suggest no uniform advantage of one ultrafiltration
method with respect to the other concerning cytokine re-
moval. Nevertheless, elimination of IL-6 may be of prog-
nostic importance, because Hauser and coworkers21 showed
that elevated IL-6 plasma levels 2 hours after CPB corre-
lated significantly with postoperative morbidity and mortal-
ity. Although TCC was lower after CUF and lactoferrin was
lower after MUF, both their concentrations in the ultrafil-
trate were extremely low, suggesting poor filtration. Even
though filtered quantities of proinflammatory markers have
mostly been small in other studies as well,5,13,15 ultrafiltra-
tion is able to reduce their plasma concentrations after the
operation and exert a modifying effect on the inflammatory
9,15,22,23
TABLE 4. Concentrations of inflammatory mediators in the
A
IL-6 in ultrafiltrate (pg/mL) 1.28 .595
IL-6 removed (pg) 1048.3 584 110
IL-10 in ultrafiltrate (pg/mL) 3.0 1
IL-10 removed (pg) 2505 886 10,56
TNF in ultrafiltrate (pg/mL) 2.83 1.83 5
TNF removed (pg) 2434.1 2305 421
TCC in ultrafiltrate (ng/mL) 62.25 194
TCC removed (ng) 73,311.6 233,174
Lactoferrin in ultrafiltrate (ng/mL) 1
Lactoferrin removed (ng) 813.6 289 75
All values not below level of detection are mean  SD.response to CPB.
1694 The Journal of Thoracic and Cardiovascular Surgery ● JunAnalysis of ultrafiltration efficacy in the literature has
focused mainly on different ultrafiltration methods. But
these various ultrafiltration methods may exert only a mod-
est influence on cytokine elimination, which instead shows
significant correlation with duration of filtration,6 and on
clinical outcome, which depends more on the amount of
fluid filtered than the ultrafiltration strategy being used.14
Instead, efficacy of ultrafiltration may depend on the prop-
erties of the filter type in use, which may differ considerably
in their performance of solute removal and clearance of
molecules. These differences are at least in part explained
by the physical characteristics of the membrane used (pore
diameter and electrostatic surface), which may inhibit cy-
tokines to be passively filtered together with plasma water
along a pressure gradient across the semipermeable mem-
brane. Generally, smaller molecules such as IL-6,6,13,15 IL-
8,9,15 TNF,6,13,15 C3a or C5a,4-6 and endothelin 111,17 have
been shown to be filtered with ultrafiltration. However, the
efficacy of removal of different molecules from the circu-
lation by ultrafiltration may be explained not only by their
molecular weights but also by different molecular confor-
mations and formation of complexes with physiologic sol-
uble inhibitors.14 Furthermore, with ultrafiltration sub-
stances are not necessarily removed from the plasma only
by convection. Barrera and coworkers24 showed that cyto-
kine binding to the membrane may be an additional mech-
anism, which could also explain the paradoxic lack of
correlation between cytokine reduction and ultrafiltrate vol-
ume found by others.6 The two filter membranes we used
demonstrate some differences in their ability to eliminate
cytokines. PAF was more effective lowering IL-10 and TCC
plasma levels, whereas PSF was more effective lowering
IL-6 and showed superior filtration quantities of TNF in the
ultrafiltrate. However, filtration of IL-10, TCC, and lacto-
ferrin was uniformly poor, as suggested by their low con-
centrations in the ultrafiltrate and their low ultrafiltrate/
plasma ratio. Other studies with different filters and
ultrafiltration methods have also found elimination of these
afiltrate and amounts removed
C D P value
.92 1.0 .02 4.6 7.08 .39
593 752.1 265 3247.3 5111 .79
25.04 3.0 3.0 .98
27894 2256 797 2066.7 495 .61
4.67 6.57 5.88 7.06 4.39 A:D  .02
4406 5107.2 4864 4750 2594 A:D  .05
6.75 21 79.66 239 .77
6075.9 19,214 54,166.9 162,501 .76
1 1 .99
263 752 266 688.9 165 .64ultr
B
1.6
0.4
0.5
7.6
.22
6.2
0
0
1
4.5inflammatory markers difficult, and it has been hypothe-
e 2004
Berdat et al Surgery for Congenital Heart Disease
CH
Dsized that their larger molecule weights inhibit efficient
filtration because their levels in the ultrafiltrate have been
uniformly low in most studies,6,9,13,15 irrespective of the
ultrafiltration method used. TNF was the only cytokine that
was filtered to a larger extent, as shown by the much higher
ultrafiltrate/plasma ratios and the large amounts of TNF in
the ultrafiltrate. TNF was significantly better filtered with
PSF than PAF, with significant differences in its concentra-
tion in the ultrafiltrate. TNF has been found to be effectively
filtered with ultrafiltration by others as well,6,13,15 with
PSF6,15,25 but also with other filter types, such as polyni-
tril.4,17 Although filtered in larger quantities with PSF, how-
ever, plasma TNF levels did not significantly differ from
those measured with PAF. This finding shows that the PSF
may not be superior to the PAF to such a degree as to
produce measurable differences in plasma TNF levels. Oth-
ers have used PSF6,15,25 and PAF6,13,15 as well, and also
different filters such as polynitril,4,17 but no one has com-
pared one filter with another directly (eg, PSF vs PAF
filters). Their results are quite comparable with ours con-
cerning performance of individual filter types. Our compar-
ison, however, shows a slightly superior profile of inflam-
matory mediator filtration of PSF compared to PAF filters,
with better elimination of proinflammatory mediators such
as TNF while anti-inflammatory mediators such as IL-10
are being withheld in the circulation, because a positive
effect of ultrafiltration by elimination of cytokines depends
on the balance between proinflammatory and anti-inflam-
matory cytokine levels after ultrafiltration.22
Although the difference was not statistically significant,
ultrafiltration volume was smaller with MUF than with CUF
in our study, in contrast to the findings of others.3,9 This
reflects our practice of prolonging CUF for the whole phase
of rewarming to maximize its potential benefits concerning
water and cytokine elimination. With MUF, however, du-
ration of filtration was limited to one to two cycles of the
total circulating blood volume passing across the filter to
keep the potentially hemodynamically unstable phase of
filtration as short as possible. MUF was therefore limited to
20 minutes. Furthermore, with MUF the total volume ac-
cessible to filtration consisted of only the patient volume
and was therefore much smaller than with CUF, during
which patient plus CPB volume was being filtered. Never-
theless, with both methods it was always possible to remove
at least the whole priming volume and reach excellent
hemoconcentration, as demonstrated by an important rise in
hematocrit in all groups.
Overall, our results seem to have been more influenced
by the filter type used than by the ultrafiltration method
applied, although differences were small. This finding puts
the ongoing discussion on which ultrafiltration method may
be the most effective into a new perspective and emphasizes
the importance of the choice of the filter type and the need
The Journal of Thoracicfor taking it into consideration during the interpretation of
study results. The power of this study may be limited by
the small groups, although other authors have also stud-
ied effects of ultrafiltration with groups of comparable
size.4-6,8,11,13,15,18,19 We decided to limit testing to the two
filter types and ultrafiltration methods routinely in use at our
institution. The presented results may not be directly com-
parable with those of others because of differences in the
methods of ultrafiltration performed in this study. In partic-
ular, MUF was not performed exactly the same way as
proposed by Elliott and associates.9 Although our method of
MUF may not allow salvage of volume from the bypass
circuit and may therefore require greater transfusion vol-
umes of blood product, we do not think that these differ-
ences influence filter performance or cytokine elimination.
The study may be further limited in not having measured the
remaining potentially important inflammatory mediators,
such as C3a, C5a, IL-1RA, and IL-8, or the activation of
leukocytes by the granulocyte surface marker CD177,
which might have shown somewhat different results. How-
ever, we chose the most important mediators from the
interleukin, complement, and leukocyte systems with
Figure 2. A, Ultrafiltrate (UF) concentrations of TNF in groups A,
B, C, and D. Asterisk indicates P < .02. B, Ultrafiltrate/plasma
ratio of IL-6 in groups A, B, C, and D. Asterisk indicates P < .02;
double asterisk indicates P < .01.known effects on the inflammatory response and clinical
and Cardiovascular Surgery ● Volume 127, Number 6 1695
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Dparameters. There is to our knowledge currently no other
study available that has directly compared different ultrafil-
tration methods and filter types in a prospectively random-
ized fashion. This study demonstrates that the contribution
of the filter type to cytokine elimination obtained by ultra-
filtration is not negligible and should be taken into consid-
eration when interpreting study results.
Conclusions
In summary, the CUF with PSF combination (group C) was
found to best eliminate IL-6, with no significant increase
during filtration, the lowest IL-6 plasma concentrations di-
rectly after filtration, and the highest ultrafiltrate/plasma
ratio. Concerning IL-10, PSF, perhaps combined with CUF,
may best retain IL-10. We found TNF to be best lowered
after MUF, and the largest amount in the ultrafiltrate was
seen after MUF with PSF (group D), suggesting that TNF is
most efficiently removed by this combination. TCC was
found to be best lowered after the use of PAF and showed
relatively large amounts in the ultrafiltrate after CUF with
PAF (group A) but also after MUF with PSF. Should
elimination of TCC be desired, PAF should not be com-
bined with MUF, since no TCC at all was found in the
ultrafiltrate after MUF with PAF (group B). Concerning
lactoferrin, we found it to rise most significantly after the
use of CUF with PAF (group A) and to be poorly filtered
with very low concentrations in the ultrafiltate of all groups.
We therefore think that the combinations we chose, espe-
cially CUF with PAF, were not suitable to eliminate lacto-
ferrin. Taken together our results suggest that PSF is ad-
vantageous for the elimination of both IL-6 (combined with
CUF) and TNF (combined with MUF) with preservation of
IL-10 (combined with CUF). On the other hand, one should
avoid PAF combined with MUF if TCC is the target and
PAF combined with CUF for lactoferrin to be efficiently
removed. Therefore the combination of CUF and MUF with a
PSF may currently be the most effective strategy to remove
inflammatory mediators in pediatric cardiac surgery with CPB.
We thank Sonja Bisch-Knaden, PhD, from the Department of
Clinical Research, and Gerhard Gillmann, from the Institute of
Social and Preventive Medicine of the University of Berne, for
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